Rise in Interleukin-2 Inhibitors Development Pipeline Accelerates

Interleukin-2 inhibitors are in high demand due to the rise in autoimmune diseases and organ transplants. DelveInsight’s report highlights 20+ pharma companies developing 22+ pipeline IL-2 inhibitors. Notable players include Corvus Pharmaceuticals, Nektar, and Merck. Key drugs like Soquelitinib and Rezpegaldesleukin show promise. Clinical trials for IL-2 inhibitors continue, with some successes and setbacks. The future looks bright for these innovative drugs.

Read more at GlobeNewswire: Interleukin-2 Inhibitors Clinical Trial Pipeline